Our clinical trial program includes the FOCUS clinical trial, a global Registration trial for patients with hepatic dominant ocular melanoma (OM). Delcath have also recently announced a new pivotal phase III trial to treat patients with intrahepatic cholangiocarcinoma (ICC). Additionally, Delcath is collecting data through our patient registry in Europe.
We believe that the Melphalan/HDS clinical development program could offer hope for patients who may otherwise have limited treatment options – potentially improving patient outcomes while reducing drug-related side effects.
For additional information on eligibility criteria and participating centers, please click on the links on this page.